---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-139561"
form_type: "8-K"
ticker: "BTMD"
cik: "0001819253"
company_name: "biote Corp."
filed_at: "2023-05-09T23:59:59+00:00"
generated_at: "2026-06-15T09:47:17.696278+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Biote Q1 revenue $44.8M (+20.7%), net loss $21.4M; launches warrant exchange offer

## Summary
- Revenue $44.8M (+20.7% YoY); gross margin 69.1% (+220 bps).
- Net loss $(21.4)M ($(0.39) per share) vs net income $9.4M in Q1 2022.
- Adjusted EBITDA $13.1M (+12.4% YoY); maintains FY 2023 guidance $190-200M revenue, $56-60M adj EBITDA.
- Offer: each outstanding warrant exchanged for 0.23 common shares; consent to convert remaining at 0.207.
- Parties representing 19.4% of public warrants and 59.3% of private warrants have agreed to tender.

## SEC filing metadata
- accession: 0001193125-23-139561
- form_type: 8-K
- ticker: BTMD
- cik: 0001819253
- company_name: biote Corp.
- filed_at: 2023-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819253/000119312523139561/0001193125-23-139561-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819253/000119312523139561/d474476d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-139561
- JSON: https://secwatch.observer/filing/0001193125-23-139561.json
- Plain text: https://secwatch.observer/filing/0001193125-23-139561.txt

## Key facts
- Earnings Releases
  biote Corp. reported first quarter ended March 31, 2023 results: revenue $44.8 million, net income $(21.4) million, EPS $(0.39) per share. Guidance reaffirmed.
  - Period: first quarter ended March 31, 2023
  - Revenue: $44.8 million
  - Net income: $(21.4) million
  - EPS: $(0.39) per share
  - Guidance: reaffirmed
  - Result: reported results
  source text: hormone therapy, today announced financial results for the first quarter ended March 31, 2023. First Quarter 2023 Financial Highlights, year-over-year: • Revenue of $44.8 million, a 20.7% increase • Gross profit margin of 69.1%, a 220-basis point increase • Net loss of $(21.4) million and GAAP loss per share of $(0.39), primarily reflecting the impact
  evidence_url: https://www.sec.gov/Archives/edgar/data/1819253/000119312523139561/0001193125-23-139561-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.